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DIFFERENTIATION OF CORD BLOOD MESENCHYMAL 
STEM CELLS TO BONE TISSUE FOR 
TISSUE ENGINEERING APPLICATIONS  
SUMMARY 
The demand for engineered bone is becoming increasingly high due to the need for 
curing traumas and fractures in clinics. Autologous bone grafts still seem to be the 
gold standards for progressive bone regeneration. However, the limitations regarding 
the produced volumes of bone grafts and donor scarcity is leading the approaches 
into finding alternative techniques to advance stable bone formation. 
Tissue engineering is a developing area that focuses on generating tissue 
replacements using arrangements of cells. In contrast to many tissues, there are may 
approaches to bone tissue engineering all involving cells, signalling molecules and 3-
D scaffolds. Still this emerging field seeks the development of viable substitutes that 
maintain the function of the human bone-tissue. Therefore, in vitro studies have been 
focused to screening the efficiency of newly designed scaffolds for in vivo utilization 
for restoring bone regeneration. Different kind of biomaterials, such as bio-ceramics, 
biopolymers, metals, and composites have been used in bone tissue engineering to 
form the bone scaffold. Scaffold materials for bone tissue engineering applications 
can be engineered to be osteoconductive, providing a substrate for tissue growth that 
helps adhesion, proliferation, and differentiated function of bone forming cells. In 
addition it is also highly desirable that the scaffold has the ability to promote ECM 
secretion, and to carry biomolecular signals.  
Mesenchymal stem cells (MSCs) comprise a population of multipotent progenitor 
cells capable of differentiating into many tissues. The diverse in vivo distribution of 
MSCs comprises mainly the bone marrow, adipose tissue, human umbilical cord, 
blood, skeletal muscles, periosteum, synovial membrane, dermis, pericytes, 
trabecular bone, lung tissue, dental pulp and periodontal ligaments. MSCs are 
reported to be isolated from various sources of tissues besides bone marrow, such as 
adipose tissue, umbilical cord blood (UCB), amniotic fluid, membrane, placenta and 
synovial tissue.   
This study primarily focuses on the use of mesenchymal stem cells derived from 
umbilical cord blood on a newly synthesized hydroxyapatite containing poly(N-
vinyl-2 prolydone-co-maleic acid) scaffold assigning the MSCs to differentiate 
towards forming bone in a 3D manner. The biomimetic essence of the study derives 
mimicking the actual fragment of human bone with respect to all necessary aspect of 
in vivo conditions, i.e.  molecular, biochemical and morphological. 
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KORDON KANI MEZENKĠMAL KÖK HÜCRELERĠNDEN  
DOKU MÜHENDĠSLĠĞĠNDE KULLANILMAK ÜZERE KEMĠK DOKU 
FARKLILAġMASI 
ÖZET 
Kemik mühendisliği uygulamalarına olan ihtiyaç, yaygın travmalar ve kemik 
kırıklarının geniş çaplı iyileştirilmesine yönelik klinik yaklaşımlar ile ilgili olarak 
giderek artmaktadır. Otolog kemik nakli halen kemik iyileşmesine yönelik 
uygulamaların başında gelmektedir. Yine de, kemik nakli için kullanılacak nakil 
örneklerinin düşük hacimleri, donör bölgelerin azlığı, sağlam ve güçlü kemik 
oluşumu sağlamak için yeni arayışların doğmasına yol açmıştır.  
Doku mühendisliği, hücrelerin yeniden organizasyonunu sağlayarak aktarılabilir 
doku örnekleri üretimine yoğunlaşmıştır. Diğer dokularla ilgili çalışmaların aksine 
kemik doku mühendisliğinde hücre, sinyal molekülleri ve 3 boyutlu yapıların 
katıldığı birçok yaklaşım vardır. Bu yüzden, in vitro çalışmalar in vivo koşullarda 
kullanılabilecek ve kemik oluşumunu sağlayacak yapay iskelet yapılarının 
verimliliğini araştırmaya yönelmiştir. Kemik oluşturmak için kullanılan yapay 
iskeletlerin yapımında biyoseramikler, biyopolimerler, metaller ve farklı bileşikler 
gibi çeşitli biyomateryaller kullanılmaktadır. Bu materyallerin, osteo-iletken, 
hücreler için tutunma yüzeyi oluşturan, hücre çoğalımını destekleyici ve 
biyomoleküler sinyallerin iletimi sağlayacak şekilde üretilmesi hedeflenmektedir.  
Mezenkimal kök hücreler, birçok farklı dokuya farklılaşma potansiyeli taşıyan 
multipotent progenitör hücrelerdir. Mezenkimal kök hücrelerin vücuttaki yaygın 
dağılımına örnek olarak, kemik iliği, yağ dokusu, kordon, kordon kanı, iskelet 
kasları, periost, sinovial zarlar, dermis, perisitler, trabeküler kemik, akciğer dokusu, 
diş pulpası ve periodontal ligamentlerde bulunabilirliği örnek olarak verilebilir. 
Mezenkimal kök hücreler, daha önce kemik iliğinden, yağ dokusundan, kordon 
kanından, amniotik sıvıdan, plasentadan ve sinavial zarlardan izole edilmiştir.  
Bu çalışma, temel olarak insan kordon kanından izole edilmiş mezenkimal kök 
hücrelerin yeni sentezlenmiş hidroksiapatit içeren poli(N-vinil-2prolidon-co-maleik 
asit) polimeri üzerinde 3 boyutlu bir şekilde kemik dokusuna farklılaştırılmasını 
hedeflemektedir. Çalışmanın biyobenzetme özü, kullanılacak olan yapının, gerçek 
insan kemik parçalarının davranışlarını in vivo kuşullarda gerekli olan moleküler, 
biyokimyasal ve morfolojik olarak taklit etmeyi amaçlamasındır.  
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1. INTRODUCTION 
 
1.1 Bone Tissue Engineering 
Tissue engineering is a developing area that focuses on generating tissue 
replacements using arrangements of cells, biological molecules, and materials. It has 
been defined as “an interdisciplinary field that applies the principle of engineering 
and the life sciences toward the development of biological substitutes that restore, 
maintain or improve tissue function” [1]. There are three general tissues engineering 
approaches; using the inductive factors promotes the healing of diseased or damaged 
tissue. Cell based therapies require gene therapy to deliver growth factors (BMP, 
VEGF, noggin) to the site of injury. Massive allografts were modified with MCS 
expressing growth factors or coated with raaV (recombinant adeno-associated 
viruses) which deliver the growth factors or inductive elements. Scaffolds can be 
modified with cells, growth factors or adhesion ligands to promote healing (Figure 
1.1). These strategies have been used in bone tissue engineering for minimize the 
bone defects [2].  
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Tissue engineering strategies [2] 
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Bone defects caused by severe trauma, congenital malformations, tumors, infections 
nonunion fractures and old ages (Figure 1.2). Bone grafts are using for reconstruction 
a large bone defect or treat poor bone- healing conditions. In the United States, there 
are ~6.5 million fractures per year according to the American Academy of 
Orthopedic Surgeons. Nearly, 15% of these fractures are difficult to heal. In addition, 
cost of healing is very expensive. For example, in 2005, 500,000 bone graft 
procedures performed in the U.S. that costing $2.5 billion [3; 4]. Up to now, the three 
most common methods to overcome the bone deficiency are autologous (bone from 
the patient), autogenous (bone from another human) and xenogeneic (bone from an 
animal source) bone transplantation. However, autografting has been the gold 
standard for bone grafting because of its advantages in osteogenic capacity, 
osteoconduction, mechanical properties, and the lack of adverse immunological 
response, it has many limitations such as the requirement of additional surgery for 
harvesting, the availability of grafts of sufficient size and shape and cost. 
Allografting is studied due to its abundant source but its usage has been limited 
because of uncertainty of compatibility and disease transmission. In addition, 
xenogeneic bone transplantation has the same limitations as allografting [5; 6].   
 
            Figure 1.2 Bone growth/losses ages in years [4] 
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To eliminate the problem of autografting and allografting, through the bone tissue 
engineering studies, suitable biodegradable scaffolds, which support the attachment, 
proliferation and migration of ostegenic cells, have been developed for effectively 
mimicing the natural process of bone repair. Bone regeneration requires the 
interaction of cells, growth factors, and extracellular matrices [7]. There have been 
many kinds of biomaterials as bone substitutes, such as ceramics, polymers, metals, 
and organic or non-organic bone substitutes [8]. Still, the important part of these 
tissue engineering strategies is dependent on having an ideal cell source for 
generating functional osteoblasts [3].  
1.1. 1 Development of Bone 
Bone is a dynamic and highly vascularized tissue that consists of a mineralized 
organic matrix formed and maintained by cells and provides remodeling throughout 
all lifetime of an individual. It plays an important role in motion, ensures the skeleton 
has enough load-bearing capacity, and serves as a protective casing for the delicate 
internal organs of the body. In addition to these structural functions, bone is 
intimately involved in homeostasis through its storage of calcium (Ca) and phosphate 
(P) ions and also regulating the concentrations of key electrolytes in the blood [9]. 
There are 206 different bones in an adult human body and 270 in an infant. Bone 
tissue itself is arranged either in a compact pattern (cortical bone) which is dense and 
organized, providing protection and mechanical support or a trabecular pattern 
(cancellous bone) that is loosely organized and highly porous and contains a 
functional vasculature and bone marrow space. As with all organs in the body, bone 
tissue has a hierarchical organization over length scales that span several orders of 
magnitude from the macro- (centimeter) scale to the nanostructured (extracellular 
matrix or ECM) components (Fig. 1.3) [6].  
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Figure 1.3:  Hierarchical organization of bone over different length scales. Bone  has 
a strong calcified outer compact layer (a), which comprises   
osteons(b).The cells are coated in cell membrane receptors that respond to 
specific binding sites (c) and the well-defined extracellular matrix (d) [6] 
Bone has three different cell types; Osteoblast, bone forming cells, secrete the 
matrix, absorb in mineral, Osteocytes are responsible for sensing and responding to 
mechanical load in bone. The third cell type is Osteoclast that remodels bone during 
the growth and in maturity. Osteoclasts remove bone to repair damage, respond to 
altered patterns of load, or provide ions for mineral homeostasis [10; 11]. 
Natural bone is formed by two mechanisms; endochondral ossification and 
intramembranous ossification (Figure 1.4). Endochondral ossification leads to the 
formation of long bones that cover the facial bones, vertebrae, apendicular skeleton 
and the lateral clavicles [12]. The process of endochondral ossification begins with 
the interaction between mesenchymal and epithelial cells cause to growth of the limb 
bud. After these events, condensation of mesenchymal precursor cells produce the 
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extracellular matrix (ECM) protein type II collagen and express the transcription 
factor Sox 9 which  is essential for chondrocyte differentiation, expression of various 
chondrocyte genes, and cartilage formation [13; 14]. The central mesenchymal cells 
in the condensate differentiate into chondrocytes and the outer cells differentiate into 
osteoblasts via growth factor including bone morphogenetic proteins (BMPs) and 
fibroblast growth factor (FGFs). These factors have very important role in skeletal 
development, repair, and regeneration. Growth factors induce chondrocytes to 
maturize to hypertrophic chondrocytes [15]. Hypertrophic chondrocytes synthesize 
an ECM which is latterly start to partially degrade and mineralized via the action of 
matrix metalloproteinases (MMPs) produced by osteoclasts [16]. So that, matrix 
becomes permissive to blood vessel invasion. This event is another important part of 
bone formation because; vascular invasion helps the flow of osteoblast, osteoclast, 
and hematopoietic cells in the formation of ossification center. At the same time of 
hypertrophic chondrocyte excitation from cell cycle, blood vessel invasion, and 
matrix degradation, mesenchymal cells surround the cartilage template, differentiate 
into osteoblasts, and lead to trabecular bone formation [17]. 
Intramembranous ossification or membrane bone formation forms directly from 
mesenchymal cells condensing at ossification centers and being transformed directly 
into osteoblasts. This process differs from the endochondral ossification in that 
cartilage is not present during ossification. Intramembranous ossification is an 
important process to healing of bone fractures [18] and formation of bonehead. The 
cranial suture lines, some facial bones, and parts of the mandible and clavicle bones 
are developed by intramembranous ossification. In that mechanism, the transcription 
factor core-binding factor (Cbfa I, also known as Runx2) regulates mesenchymal 
precursor cell differentiation into osteoblasts. These osteoblasts produce a matrix rich 
in collagen type I, proteoglycans and non-collagenous protein (for example, 
osteocalcin, bone sialoprotein). After this, matrix constructs nucleation and growth of 
minerals, principally hydroxyapatite. During this time osteocytes cells occur from 
some osteoblasts that trap in the mineralized matrix. As a mineralization progresses, 
mesenchymal cells form a layer that surrounds the bone, named periosteum, and this 
layer plays a key role in bone modeling and remodeling procedures [19; 20]. 
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Figure 1.4: Development of bone for bone tissue engineering [12]. 
1.1.2 Fracture Healing of Bone 
Fracture healing is a process in the human body that resemble the skeletal 
development and many variables take place in the injury site, such as growth factors, 
nutrients and hormones, the electrical environment and mechanical stability.  
Fracture healing initiated by activation of the immune system. This activation 
supports the mitogenesis of undifferentiated mesenchymal cells and lead to the 
formation of oseoprogenitor cells that form new bone. There are four different stages 
for fracture healing that is based on the result of histological observations of healing 
fractures in both human patients and animal models. However, researchers showed 
that the molecular forces that incorporate into process are pro-inflammatory 
molecules [interleukin 1 (IL-1), the interleukin 6 (IL-6), tumor necrosis factor  (TNF-
A)] that initiate the repair cascade, growth factors and pre-osteogenic factors 
[transforming growth factor b (TGF-b), platelet-derived growth factor (PDGF)], 
metalloproteinases and angiogenetic factors  (Figure 1.5) [21; 22; 23]  
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Figure 1.5: Bone fracture healing process [21] 
The first stage of fracture healing is inflammation. A fracture is typically associated 
with disruption of the local soft tissue integrity, interruption to normal vascular 
function, and a distortion of the marrow architecture. A hematoma occurs in the 
bleeding site of fracture by the surrounding tissue. Degranulating platelets, 
macrophages, and other inflammatory cells (granulocytes, lymphocytes, and 
monocytes) do not let  the hematoma to flow and struggle with infection, secrete 
cytokines and growth factors, and advance clotting into a fibrinous thrombus [24; 
25].  With time, capillaries grow into the clot, which is re-organized into granulation 
tissue. Macrophages, giant cells and other phagocytic cells clear degenerated cells 
and other debris.  
After this event, soft callus formation is started. This stage is mastered on a cellular 
level by chondrocytes and fibroblasts dependent on fractures. These cells produce a 
semi-rigid soft callus that can provide mechanical support to the fracture, and also 
act as a template for the bony callus that will later substitute it. Chondrocytes derived 
from mesenchymal progenitors proliferate and synthesize cartilaginous matrix until 
all the fibrinous/granulation tissue is replaced by cartilage. Where cartilage 
production is deficient, fibroblasts replace the region. Different cartilaginous regions 
increasingly grow and unite to produce a central fibrocartilaginous plug between the 
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fractured fragments that supports the fracture [26]. In the final stages of soft callus 
production, the chondrocytes undergo hypertrophy and mineralize the cartilaginous 
matrix before undergoing apoptosis. 
The third stage, also known as primary bone formation, is hard callus formation. The 
characteristic feature of stage is the most active osteogenesis. It is characterized by 
high levels of osteoblast activity and the formation of mineralized bone matrix. 
Osteoblast activity increases directly in the peripheral callus in areas of stability. 
With the formation of mineralized bone matrix, the new bone, hard callus, is formed 
with revascularization. Hard callus is typically irregular and under-remodeled. The 
initial bone matrix includes a combination of proteinaceous and mineralized 
extracellular matrix tissue. This is synthesized by mature osteoblasts, which 
differentiate from osteoprogenitors in the presence of osteogenic factors. Members of 
the BMP family are critical mediators of this process [24; 27; 28]. The vasculature is 
known to be critical for formation of the hard callus. Because increased oxygen is 
necessary for osteoblast differentiation. In model system, angiogenic factor for 
stimulation of vessel formation can increase bone formation and fracture healing 
[29].  
The final stage of fracture repair comprises the remodeling of the woven bone hard 
callus into the original cortical and/or trabecular bone configuration. This phase can 
also be referred to as secondary bone formation [24]. Initially, the irregular woven 
bone callus converted into lamellar bone, although the standard cortical structure is 
eventually restored. The remodeling process is continued by bone resorption and by 
the formation of lamellar bone. The cell involving the resorption of mineralized bone 
is the osteoclast which is a large multinucleated cell, is formed by the differentiation 
and fusion of haematopoietic precursors [30]. To effect remodeling, osteoclasts 
become polarized and adhere to a mineralized surface. They form a wavy periphery, 
which close the resorption domain and pumped acid and proteinases. The acid 
environment demineralizes the matrix, while proteinases degrade the organic 
components, such as collagen. The degradation products are removed through a 
vesicular pathway from the wavy periphery to the functional secretory domain and 
the osteoclasts are either apoptosed or return to the non-resorbing form. Bone 
resorption by osteoclasts creates erosive pits on the bone surface known as 
9 
 
“Howship’s lacuna”. Once completed, osteoblasts are able to lay down new bone on 
the eroded surface [22].  
Two principal cytokines that are secreted by osteoblasts are critical for the induction, 
survival and competency of osteoclasts: M-CSF and Receptor Activator of NF_B 
Ligand (RANKL). M-CSF is important for the primary induction of haematopoietic 
stem cell differentiation towards an osteoclast lineage. RANKL is a factor produced 
by mature osteoblasts that is responsible for the coordination of bone formation and 
bone resorption [31; 32].  
1.2 Stem Cells in Bone Tissue Engineering 
Stem cells have a wide application potential in bone tissue engineering field. There 
have been several reports that showed the utilization of stem cells from various 
sources for bone tissue formation. Bone regeneration by osteoblasts or by osteoblast 
progenitor cell transplantation is one of the most promising techniques being 
developed. The potential of this technique to eliminate the problems of immune 
rejection, donor scarcity and pathogen transfer is crucial in many ways [33]. As a 
first main step toward the use of stem cells in bone tissue engineering osteoblasts and 
osteoblast progenitors obtained from donor bone marrow were expanded in culture 
[34] and transferred onto a specific degradable scaffold, which will gradually 
degrade as cells grow and secrete new bone in vivo [35]. Bone regeneration in vivo 
comprises osteogenic reparative cells deriving from mesenchymal stem cells (MSCs) 
in bone marrow at the presence of a regeneration template such as bone architecture 
structure and the influence of regulatory signals [36]. Additionally, other cell sources 
compared mesenchymal stem cells isolated from bone marrow such as adipose tissue 
and umbilical cord blood are found to be promising precursors capable of 
differentiation into osteoblast-like cells [37]. Adding to that, other types of stem cells 
such as embryonic stem cells [38], dermal fibroblasts [33], dental tissues [39] or 
muscle cells, can be induced  for bone tissue regeneration. It is crucial to note that 
the transcription profiles of bone marrow mesenchymal stem cells have also shown 
to be more efficient in the process of differentiation into fully mature osteoblasts 
[40].  
MSCs derived from bone marrow are the primary source of osteogenic cells. Yet, 
there are obvious requirements to develop techniques for their expansion in culture 
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environment, and the design of specialized scaffolds that can support and enhance 
their potential for osteogenic differentiation and functional efficiency into the 
engineered bone.  An ideal stem cell source for bone tissue engineering should have 
the capacity to initially proliferate and then differentiate in vitro, in a reproducibly 
controlled manner. Another crucial parameter is the type and the maturity of the 
selected cells which also have influence on the nature of the regenerative response. 
Additionally, scaffold requirements for bone tissue engineering comprise 
osteoconductive or osteoinductive potential, high porosity with large interconnected 
pores to enable mass transport of molecules, infiltration of cells, biocompatibility and 
lastly degradability over an appropriate time scale [36]. 
Embryonic Stem Cells (ESCs) have also been reported to be utilized for bone tissue 
engineering. However ESCs have a pluripotent nature, use of them are not readily 
legalized and still raises ethical concerns among the scientific community. Adding to 
that, in animal studies the investigations are focused to determine which cell 
population derived from the ESCs is responsible for bone deposition given the fact 
that a subpopulation of mesodermal or osteoprogenitor cells might be present in the 
seeded heterogeneous ESC population to be differentiated into osteoblasts and 
deposit the bone tissue [38]. There is also a problem in using ESCs for renewal of 
adult tissues regarding their low efficiency and long differentiation time to turn into 
functional adult cells. These problems might be overcome by using adult precursor 
cells or by directing ESCs to specialize via a certain pathway because of the fact that 
ESCs require a series of differentiation, signals to produce progeny of a more 
differentiated type of cell [41].  
The bone tissue engineering process mainly comprises the isolation of osteogenic 
cells from a donor, expansion of them in the culture environment, seeding the cells 
onto a specific scaffold that will degrade as cells assemble the new bone. They can 
be either cultured in vitro or implanted directly to the recipient to enhance bone 
formation or repair a fracture in vivo. As discussed before, the cells that can be the 
primary candidates for bone formation are the ones that can be differentiated 
efficiently to bone cells with the proper regulatory signals such as multipotent 
Mesenchymal Stem Cells [36], pluripotent Embryonic Stem Cells (ESCs) [38], and 
certain unipotent cells that can be de-differentiated to re-differentiated into another 
type of cell [42]. This study mainly focuses on the use of MSCs for primary source 
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of osteogenic precursors. In order to understand the concept of differentiation one 
should observe the potentials and the source of stem cells. 
1.2.1 Source of Stem Cells 
By definition, “Stem cell is a single cell that can give rise to progeny that 
differentiate into any of the specialized cells of embryonic or adult tissues”. The 
ultimate stem cell is the fertilized egg that divides several times to give rise to lines 
of cells that form various differentiated tissues responsible for a specific purpose 
[41]. Additionally, in many tissues they behave as an internal repair system, dividing 
without limit to replenish other cells. When a stem cell divides, each new cell can 
remain a stem cell or become another type of cell with a more specialized function, 
such as a bone cell, a red blood cell, or a liver cell [43]. The potency of the stem cell, 
which is the capacity to differentiate into specialized cell types, decreases gradually 
when the cell becomes more and more differentiated and specialized [44]. During the 
early divisions of the fertilized egg, each daughter cell conserves its totipotency. 
Through a series of divisions, the totipotent embryonic stem cells (ESCs) lose 
potential and gain a differentiated function (Figure 1.6).  
 
      
 
 
 
 
 
 
 
 
 
 
                     Figure 1.6: The Embryonic Stem Cell (ESC) lineage [41].  
Stem cells have been defined in many ways but they should carry three main 
principles. First, a stem cell must be capable of self-renewal, which is, undergoing 
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symmetric or asymmetric divisions through which the stem cell population is 
maintained. Second, a single cell must be capable of multilineage differentiation, 
which is defined as potency before. The third principle is the in vivo regeneration of 
tissues. These properties of stem cells make them uniquely suited for regenerative 
medicine, tissue repair and gene therapy applications [45].  
 
 
 
 
 
 
 
 
 
Figure 1.7: Embryonic Stem Cells produce many subtypes of stem cells at many                                                                            
d               levels that eventually produce the various types of cells in the body (Left).  
D               Actual embryo micrograph showing the ESCs (Right) [44]. 
 
To be more precise, in terms of potency one needs observe the hierarchy of the stem 
cells. As described before, totipotent stem cells can differentiate into embryonic cell 
types that are produced from the fusion of the sperm and egg. These cells can give 
rise to any of the nearly 220 types of cells in the body, and can build a complete 
living organism (Figure 1.7) whereas pluripotent stem cells are the descendants of 
totipotent cells and can differentiate into almost all types of cells. They are the cells 
derived from any of the three germ layers (endoderm, mesoderm and ectoderm) with 
the ability to form trophoblasts. A more differentiated state of pluripotent cells are 
defined as multipotent stem cells which can differentiate into but a limited number 
of lineages, that of a closely related family of cells such as hematopoietic cells, stem 
cells which can normally develop into several types of blood.  A further step of 
differentiation leads a multipotent cell to be an oligopotent stem cell, the cell that 
can differentiate into only a few types of cells, such as myeloid stem cells. A final 
step of differentiation leads the stem cell to be a unipotent stem cell, that can 
produce only their own cell type of cells, such as muscle stem cells, still conserving 
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the property of self-renewal that distinguishes them from a somatic cell (Figure 1.8) 
[44]. Properties of stem cells can be distinguished using certain methods like 
clonogenic assays, in which single cells are characterized by their capacity to 
differentiate and self-renewal. Besides, stem cells can also be defined regarding the 
presence of distinctive set of cell surface antigens [46].  
 
Figure 1.8: Development of the embryo [44]. 
Throughout normal tissue renewal in adult organs, the stem cells of that tissue give 
rise to a descent that differentiates into mature functioning cells in the tissue. Stem 
cells that lie beneath the totipotency are also called progenitor cells. In adult 
organisms, stem cells/progenitor cells act as a repair system for the body, 
replenishing specialized cells, but also maintaining the normal turnover of 
regenerative organs, such as blood, skin or neural tissues. Aside from the cells at 
germination phase, that conserve their totipotency, most stem cells in adult tissues 
have a reduced potency level, which limits them to produce different types of cells. 
Yet, there have been several studies that showed the presence progenitor cells in a 
given tissue in the adult body (Figure 1.9).  
 
 
 
 
 
 
 
14 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: Symmetric and Asymmetric division of stem cells (Left);Model of tissue       
d                  renewal (Right) [41]. 
The adult body contains two types of stem cells: hematopoietic cells which can 
differentiate into blood cells and the less differentiated mesenchymal stem cells. In 
this study, as mentioned before our primary focus is a specific subtype of multipotent 
stem cells that  is the mesenchymal stem cell (MSC), which became popular in stem 
cell research regarding their ease of isolation from the tissues in which they are 
present. The diverse in vivo distribution of MSCs comprises mainly the bone 
marrow, adipose tissue, human umbilical cord, blood, skeletal muscles, periosteum, 
synovial membrane, dermis, pericytes, trabecular bone, lung tissue, dental pulp and 
periodontal ligaments (Figure 1.10) [45; 47].  
Hematopoietic stem cells are located in the bone marrow and they are the 
undifferentiated stem cells that produce blood cells. Blood is one of the most rapidly 
replaced tissues in the body. The lineage of blood cells extends from a pluripotent 
stem cell, to precursor cells, and finally maturated circulating blood cells. Most of 
the circulating blood cells cannot proliferate such as erythrocytes do exclude their 
nuclei and can only survive for several months. There is also of the large number of 
poly-morphonuclear cells in blood that require rapid renewal regarding the immune 
system, this case requires an enormous number of precursor cells. These precursor 
cells are present in the bone marrow as blast cells. The number of proliferating 
hematopoietic progenitor cells has the probability of 0.05% of the total number of 
bone marrow cells. In addition to the hematopoietic precursors, bone marrow also 
contains mesenchymal progenitor cells/stem cells that can give rise to many other 
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types of cell, such as osteocytes, adipocytes, muscle cells, astrocytes, and neurons, as 
well as stromal cells that help hematopoiesis [48; 49]. MSCs have also been isolated 
from various sources of tissues besides bone marrow, such as adipose tissue, 
umbilical cord blood (UCB), amniotic fluid, membrane, placenta and synovial tissue 
[50]. 
Current evidence suggest that not only the bone marrow contains a multipotent blood 
forming stem cells, but it also contains a group of stem cells that has the potential to 
circulate the body and repair other non-hematopoietic tissues [41]. 
 
 
 
 
Figure 1.10: Stem Cells by origin [51]. 
1.2.1.1 Mesenchymal Stem Cells 
As described before mesenchymal stem cells are multipotent stem cells that have the 
capacity to form hematopoietic cells and many types of other varying from 
adipocytes to osteocytes. In order to define the exact nature of the MSCs one should 
observe the origins. MSCs are derived from mesenchyme, which is a type of loose 
reticular connective tissue derived from all three germ layers in the embryo. The 
early mesenchyme is derived from the mesoderm, which primarily differentiates into 
hematopoietic, and connective tissues. MSCs are also referred as mesenchymal 
progenitor cells and marrow stromal cells [52] because of their potential to form 
various mesenchymal tissues. In fact during the embryogenic stages the developing 
organism locates the progenitor cells necessary for tissue maintenance within 
different tissues for repair in the adult life [41].  
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The presence of mesenchymal progenitor cells within the bone marrow was first 
shown by Goujon in the late nineteenth century. Accumulating information on MSCs 
have been increasing rapidly especially in the last decades because of the recent 
advances in technology paving the way to determine many characteristics of the stem 
cells such as the developing microscopy techniques, genomics, proteomics  and bio-
assays. Through the manipulations of MSCs the potential of them is gradually 
revealing itself.    
Mammalian bone marrow is thought to contain three different cellular systems that 
are, hematopoietic, endothelial and stromal systems. MSC are commonly found in 
the stromal compartment of bone marrow also referred as bone marrow stromal cells 
[52]. Stromal cells were defined as being mesenchymal that contains marrow derived 
stromal cells/MSCs and all their progeny within [53]. It is also recently reported that 
the adult mammalian bone marrow microenvironment does actually comprise two 
main morphologically and functionally distinct populations of precursor cells which 
are MSCs, that primarily give rise to the musculoskeletal tissues and hematopoietic 
stem cells, HSCs, that give rise to types of blood cells. There is also an interaction 
between the two systems because of the fact that cells of mesenchymal origin 
maintain hematopoiesis ability [54]. 
While MSCs are primarily isolated from bone marrow, they are also found in a 
various adult tissues comprising adipose tissue, periosteum, trabecular bone, skeletal 
muscle, synovial tissue, dental pulp, central nervous system, dermis, liver, spleen, 
kidney, thymus, lung, pancreas, tendons and ligaments, blood [51], umbilical cord 
blood (UCB), amniotic fluid, membrane, placenta [50].  
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Figure 1.11: Mesenchymal Stem Cells within Umbilical Cord [18]. 
 
Morphologically, MSCs are characterized by a small cell body with a few cell 
processes, which are long and thin. The cell body contains a large, round nucleus 
with a distinctive nucleolus surrounded by homogenously dispersed chromatin 
particles. The cytoplasmic appearance contains a small amount of Golgi apparatus, 
rough endoplasmic reticulum, mitochondria, and polyribosomes [18]. As seen in 
Figure 1.11 the cells are widely dispersed and the adjacent extracellular matrix is 
populated by a few reticular fibrils.   
Differentiation of MSCs is conducted through growth factors and cytokines such as 
transforming growth factor-beta (TGF-β), fibroblast growth factor (FGF) and bone 
morphogenetic protein (BMP), hormones such as dexamethasone. Ascorbic acid 
(vitamin C) and chemicals such as β-glycerophosphate also play a crucial role in the 
cellular response. It also defined that the major signaling pathways in the crosstalk 
such as Notch, Wnt, BMP and transcriptional factors like Runt homology domain 
transcription factor (Runx) plays role at cell fate [55].  
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Despite of the growing knowledge about MSCs, there is no widely accepted absolute 
definition of of MSC in terms of molecular markers, there is only functional 
definitions. In vitro utilization of MSCs mainly results in a heterogenous population 
of cells a minor proportion have clonogenic potential which makes it harder to 
discriminate the MSCs. A surface marker STRO-1 is used to isolate stromal 
precursor cells in fresh human bone marrow suspension. STRO-1 does not bind to 
hematopoietic progenitor cells; however, it binds to nearly 10% of bone marrow cells 
that contain glycophorin A, so STRO-1 is not sufficient to purify a bone marrow 
population totally [56]. Still, there is a panel of markers such as CD44, CD71, CD29, 
CD90, CD105, CD106, CD120a, CD124, SH2, SH3, which are surface antigens used 
to select pure populations of MSCs [57]. It is also crucial to note that up to now, 
there is no significant difference observed between the MSCs and fibroblasts 
regarding their morphology and immune features [58]. 
The potential use of adult MSCs for tissue engineering and stem cell therapy 
applications appears to be increasing while the main shortage is the scarcity of these 
cells in tissues and the difficulty with isolation of them. Current isolation methods 
used to obtain MSCs for tissue engineering are based on adherency to tissue culture 
plates, density gradient centrifugation, the use of magnetic beads, size elimination 
methods, cell sorting based on surface antigens or varying combinations of these 
methods [51].   
This study primarily focuses on the use of mesenchymal stem cells derived from 
umbilical cord blood on a newly synthesized hydroxyapatite containing scaffold 
assigning the MSCs to differentiate and form bone in a 3D manner. The biomimetic 
essence of the study derives from the engineering solution to mimic the actual 
fragment of human bone in a molecular, chemical and morphological way. To be 
more specific on the subject, the potential and applications of MSCs derived from 
umbilical cord blood will be discussed.  
At first, it was not clear whether umbilical cord blood contained MSCs in significant 
numbers.  After that it has reported that sub-endothelial layer of the umbilical cord 
vein contains MSCs that can be expended in significant numbers in vitro. Currently, 
it is widely accepted that umbilical cord blood is a source for hematopoietic stem 
cells and transplantation and preservation of cord blood has become a part of clinical 
practice since the late 1990s. In addition, it have been demonstrated that there is a 
19 
 
 potential of umbilical cord blood derived MSCs for tissue engineering with the 
production of the osteocyte, adipocytes, myocyte and chondocyte descents from 
umbilical cord blood MSCs (Figure 1:12). 
 
Figure 1.12: MSCs can differentiate into osteocyte, chondrocyte, myocyte and adipo 
d                    cytes  cells and can be induced to form each kind of  connective  tissues  
h                    by a suitable in vitro environment [86]. 
Up to now, the most common source for MSCs in clinical applications has been the 
bone marrow, yet aspirating the bone marrow from the patient/donor is a highly 
invasive procedure. Besides, it has been shown that the number of the MSCs that 
preserve their potency in bone marrow decreases with age [59]. Consequently, the 
utilization of the alternative sources of MSCs is crucial in terms of eliminating the 
disadvantageous features of bone marrow MSCs. Cord-blood has proven to be a 
clinically valuable source for hematopoietic stem cells with many valuable clinical 
applications [60; 61].  It is also important to note that MSCs deriving from different 
sources differ in their potential for differentiation and their differentiation kinetics, 
especially in their adipogenic differentiation potentials. Despite the fact that isolation 
yield of MSCs from umbilical cord blood is low (30%) [61], MSCs from umbilical 
cord has similar degree of capacity to differentiate osteocytes and collecting the 
MSCs from this source is advantageous in terms of the presence of a non-invasive 
procedure.   
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 1.3 Scaffolds for Bone Tissue Engineering 
Organ and tissue loss or failure resulting from an injury or other type of damage is a 
major health problem. In recent years, many people died due to the lack of donor 
organs or efficient organ substitutes. Actually, significant advances have been made 
in medical techniques but transplantation of organs or tissues is still a widely 
accepted therapy to treat patients. The transplantation of tissues taken from patients 
known as autologous transplantation is limited because of donor site morbidity and 
infection or pain to patients due to secondary surgery. Alternative way is the 
availability of a donor organ but its main problem is immunogenic responses of the 
patient against the transplanted organ [62]. Other available therapies including 
surgical reconstruction, drug therapy, synthetic prostheses, and medical devices are 
not limited by supply, but they have other problems. For example, synthetic 
prostheses and medical devices are not able to replace all the functions of a damaged 
or lost organ or tissue. Tissue engineering has emerged alternative approach to treat 
the loss or malfunction of a tissue or organ without the limitations of current 
therapies [63]. A long term goal for tissue engineering is to control and regulate the 
potential of natural tissue regeneration for defect repair or organ regeneration. For 
that, tissue engineering has been developed to design artificial biocompatible 
materials for replacement of irreversibly damaged tissues and organs [64]. 
Tissue engineering has a broad range of applications comprising a highly developing 
area, bone tissue engineering. It should offer the possibility to regenerate damaged 
tissue, replacing broken tissue, or even creating new “bone”. However, incorporating 
the elements present in natural bone formation into bone tissue engineering is a 
challenging task, because the bone as an organ is dynamic and complex. The bone 
structure is composed of inorganic hydroxyapatite (HA) and the organic matrix 
containing mostly (95%) collagen type I. The morphology of the bone has also been 
described as a porous (50–90% porosity) tissue depending on the bone type. The 
general aim for bone tissue engineering is to generate materials that: (1) mimic the 
structural and cell-interactive properties of the bone extracellular matrix; (2) contain 
key molecules for bone regeneration; (3) support cells capable of forming bone tissue 
[4; 62; 65]. Therefore, biomimetic approach is to use the natural bone as a guide for 
the development of bone encouraged by a composite with improved mechanical 
properties and enhanced biocompatibility. Recently, studies of three-dimensional 
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scaffold materials became a critical element for mimicry of the bone structure, 
morphology to facilitate the growth of vasculature into the material and provide an 
ideal environment for bone formation [66].  
1.3.1 Scaffold Design Criteria 
Different kind of biomaterials, such as bioceramics, biopolymers, metals, and 
composites have been used in bone tissue engineering to form the bone scaffold.  In 
general, to stimulate cellular functions, several important characteristics of scaffolds 
can be described as biocompatibility, biodegradability, reproducibility, processability 
into three-dimensional structure, mechanical compatibility, high porosity with 
interconnected pores, and no potential of serious immunological effects or foreign 
body reactions. Some scaffold materials can be engineered to be osteoconductive, 
providing a substrate for tissue growth that helps adhesion, proliferation, and 
differentiated function of bone forming cells. In addition it is also highly desirable 
that the scaffold has the ability to promote ECM secretion, and to carry biomolecular 
signals [4]. 
Because of easy manipulation, design flexibility and functional properties, polymers 
are the most useable materials for making scaffolds. Polymers are classified as either 
naturally derived polymers or synthetic polymers. The naturally derived polymers are 
collagen and glycosaminoglycan, alginic acid, chitosan, and polypeptides. These 
polymers are proteins of the native extracellular matrices. Collagen is the most 
widely used natural polymer for making scaffolds and its functional properties are 
making it usable for cellular growth. Collagen extracted from natural sources causes 
immunogenic responses so the direct usage of collagen is limited. The main 
disadvantages of using collagen are the rapid degradation rate and weak mechanical 
properties. Collagen fibers have also been cross- linked to retard the degradation rate 
[63].   
Frequently used biodegradable synthetic polymers are poly(lactic acid) (PLA), 
poly(glycolic acid) (PGA), poly(lactic-coglycolic acid) (PLGA), poly(ε-
caprolactone)(PCL) and poly(lactic-cocaprolactone) (PLA-CL). US Food and Drug 
Administration (FDA) approve their usage for certain biomedical applications. One 
of most important feature of synthetic polymers is biodegradation rate. The rate 
matches with the speed of new tissue regeneration at the defect site. If the scaffold 
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degradation rate is more rapid than the tissue regeneration, the carrier function of 
scaffold for cell growth will be broken; on the other hand slow degradation of 
scaffold prevent tissue regeneration. In table 1.1 the degradation characteristics of 
various synthetic polymers have been listed [67]. In addition to degradation rate, 
certain physical properties of the scaffolds must be considered. To induce tissue 
growth, scaffold must have to a large area to allow cell attachment. This is usually 
done by creating a highly porous polymer so that cells can penetrate the pores, and 
the pores must be interconnected to facilitate nutrient and waste exchange by cells 
deep within the construct [68].   
Table 1.1: Biodegradable synthetic polymers and their degradation rates [67]. 
 
 
Most synthetic polymer biomaterials have noncharged elements in their composition 
so it cause low surface wettability. Such hydrophobic surfaces are undesirable 
because osteogenic cells show a lower proliferative and a higher apoptotic rate on 
hydrophobic surfaces than on hydrophilic surfaces. Also, these polymeric 
biomaterials have bioinert surface that lacks bioactive functions for bone formation, 
so bioinert surface is evoking minimal tissue responses [69; 70]. One of the most 
attractive synthetic polymers is Poly(lactic acid) (PLA) and its copolymer due to 
their favorable biocompatibility and controllable biodegradability. Actually, their 
acidic degradation products may cause inflammatory response in the host tissue. On 
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the other hand, polymers such as PLA and poly(e-caprolactone) (PCL) are  non 
osteoconductive. Certain bioactive ceramics such as tricalcium phosphate (TCP) and 
hydroxyapatite (HA), react with physiological fluids to form tenacious bonds to hard 
(and in some cases soft) tissue. These ceramics are being considered for clinical 
application but they are stiff, brittle, and difficult to form into complex shapes. In 
order to search better scaffolds for bone tissue engineering, a composite strategy can 
be adopted. Composites including the polymers with bioceramics can be used as 
tissue engineering scaffolds. Combination of them can serve two purposes; (a) 
making the scaffolds osteoconductive, and (b) reinforcing the scaffolds. [71]. 
According to the literature search Poly(N-vinyl-2 pyrrolidone-co-malec acid) (P(VP-
co-MAN)) has never been used before as a scaffold for bone tissue formation. 
Adding to its potential to serve as an efficient scaffold it is also advantageous 
because of the fact that it is hydrophilic and gained the osteoconductive properties 
when combined with hydroxyapatite which is required for osteogenic cell formation 
from mesenchymal stem cells. 
1.3.2. Hydroxyapatite/Poly(N-vinyl-2-pyrrolidone-co-malec acid) Scaffold 
Poly(N-vinyl-2-pyrrolidone-co-maleic anhydride) (P(VP-co-MAN)) is the 
copolymerization product of N-vinyl-2-pyrrolidone (NVP) and maleic anhydride 
(MAN) and carries the properties of its monomers in non-toxic form. P(VP-co-
MAN) hydrolyzes in water to give poly(N-vinyl -2-pyrrolidone-co-maleic acid) 
(P(VP-co-MA)) which is highly soluble in water [72].  
 
 
 
      
Figure 1.13: Synthesis of poly(N-vinyl -2-pyrrolidone-co-maleic acid) 
Because of having amid group, P(VP-co-MA) is a potential target of peptidases like 
do in PVP. Also, P(VP-co-MA) has additional carboxylic acids groups coming from 
maleic acid units. The maleic acid units increases the biodegradation possibility of 
P(VP-co-MA) because polymaleic acid is biodegradable [73; 74]. Moreover, metal 
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binding property of P(VP-co-MA) can make it possible to bind P(VP-co-MA) to 
hydroxyapatite and construct a biodegradable composite [75].  
P(VP-co-MA) polymer is biodegradable, soluble in water and highly hydrophilic. 
Thus, in the composite synthesis reaction, it was not necessary to use organic 
solvents in order to solve the polymer. Organic solvents are toxic to cells and usually 
remain at trace amounts in scaffolds even after purification steps. Furthermore, 
hydrophilicity may allow cells to attach scaffolds earlier. Thus, it can solve 
osteointegration problems of some implants. Due to the presence of many 
electrophilic groups, P(VP-co-MA) chealates with metals it can be used in tissue 
engineering area Thus, it may also chelate with calcium ions found at hydroxyapatite 
or initiate hydroxyapatite formation in presence of calcium and phosphor ions. P(VP-
co-MA) has significant anti-inflammatory effect [76]. This property decreases the 
risk of host rejection of the scaffold significantly. P(VP-co-MA) is produced in 
anhydride form (P(VP-co-MAN)) which is very reactive polymer. Thus, some drugs 
[76; 77], sugars [78], peptides [79], proteins [80] and enzymes [81] have been 
coupled to this polymer. The polymer releases the coupled compound slowly in 
water. Thus, it allows us to conjugate many things such as growth factors, for bone 
tissue engineering and release them slowly. 
The three-dimensional scaffold materials were designed to mimic one or more of the 
bone-forming components of autograft, in order to facilitate the growth of 
vasculature into the material, and provide an ideal environment for bone formation. 
Many researchers have prepared hydroxyapatite (HA) and collagen composite by 
mixture or self-organization, followed by cross linkage or uniaxial pressing to 
develop a large size material. However, its mechanical properties were too weak for 
practical application. In order to improve the mechanical strength and the forming 
ability of the material, hydroxyapatite and polymers are combined [82]. Based of 
these knowledge hydroxyapatite was crosslinked the P(VP-co-MA) make 
biocompatible, biodegradable, osteoinductive and osteoconductive scaffolds with 
high osteointegration properties [83]. 
1.4 Aim of the Study 
Biodegradable polymeric constructs for bone tissue engineering are 3D structures 
that allow bone cells to attach and reproduce on them. Because of biodegradability of 
the polymers, they are not permanent in the body and are degraded gradually while 
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bone cells are proliferating. Thus, bone cells replace the scaffold in time healing of 
defected sides. 
Although poly(N-vinyl-2-pyrrolidone-co-malec acid) has many advantages upon to 
other polymers, there is no available study on poly(N-vinyl-2-pyrrolidone-co-malec 
acid) for bone tissue engineering according to the literature search. Mimicking bone 
biomineralization process by crosslinking hydroxyapatite with poly(N-vinyl-2-
pyrrolidone-co-maleic acid) makes it osteoinductive and osteoconductive with high 
osteointegration properties for bone defect applications. In this study, we studied the 
effect of cells on Hydroxapatite/Poly(N-vinyl-2-pyrrolidone-co-malec acid) scaffold, 
which was previously developed by our group members (Erdem Tezcan,[83] ) was 
synthesized.  
Recent studies have demonstrated that mesenchymal stem cells derived from human 
umbilical cord blood (CBMSCs) have been characterized by their multipotency to 
differentiate into mesenchyme-lineage cell types, including chondrocytes, 
osteoblasts, and adipocytes. Nevertheless, nobody observed the effect of any scaffold 
on osteoblasts, which are differentiated from mesenchymal cells that derived from 
human umbilical cord blood. 
In the scope of thesis, we investigate the effect of HA/P(VP-co-MA) on osteoblast 
proliferation and differentiation upon seeding CBMSCs, leading to the formation of 
adequate tissue substitutes for the regeneration of bone defects. For this aim, we 
isolated the mesencymal stem cells from the human cord blood and cultured them in 
humidified atmospheric conditions. Next, characterization of the cells was performed 
by detection of CD 44, CD90 and CD105 surface markers. Cells were seeded on the 
HA/P(VP-co-MA) and induced for differentiation into osteoblast cells. 
Morphological analysis and mineralization assay were done at regular time intervals. 
Based on the results, HA/P(VP-co-MA) and CBMSCs combination were shown to 
be effectively used for repairing the bone defects towards regenerative bone tissue 
engineering applications.  
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2. EXPERIMENTS 
2.1 Materials and Laboratory Equipments 
2.1.1 Used Equipments 
The laboratory equipment used in this study is listed in Appendix A. 
2.1.2 Used Chemicals and Markers 
The chemicals and markers used are given in Appendix B together with their 
suppliers. The compositions and preparation of buffers and solutions are given in 
Appendix C. 
2.1.3 Collection of Human Umbilical Cord Blood 
Cord blood was collected from the umbilical cord immediately after the birth of the 
baby and after the cord has been cut. It was done using a specific kit. The term 
umbilical cord blood of newborns was collected and processed within 24h. Samples 
were obtained from informed normal individuals providing collections for allogeneic 
transplantation according to procedures approved by the Local Ethical Committee.  
2.2 Methods 
2.2.1 Isolation and Culture of Cord Blood Mononuclear Cells  
The isolation of cord blood mononuclear cells was done with Ficol Paque Plus and 
rossettasep from stem cell technologies. 
1. 4 ml of unprocessed cord blood was mixed with 200 ul Rossettasep for 20 
minute. 
2. Samples were diluted with an equal volume PBS+ 2% FBS 
3. 8 ml of diluted cells were carefully layered on 6 ml Ficoll- Paque Plus in 15 ml 
conical tube. They were centrifugated at 1800 rpm for 25 minute. 
 
28 
4. The mononuclear cells were carefully harvested from the buffy layer located the 
interface between the medium and Ficoll - Paque plus by using a 5 ml pipet. 
5. Cells were diluted with equal volume of PBS+ 2% FBS and centrifuge at 1500 
rpm for 5 minute. 
6. Supernatant was discarded, cell pellet was resuspended, and washed once using 
PBS+ 2% FBS. 
7. Nucleated cells were counted using a hemocytometer and a light microscope. 
Cells were resuspended in complete medium (Table 2.1) at 10
7
mononuclear 
cells/ml. 
8. 10 ml of complete medium was placed into a T-25 tissue culture flask and added 
200 ul of stock cell solution (2 x 10
6
 cells per flask). 
9. The cap was placed onto the flask following the addition of cells and swirled the 
flask gently to ensure equal distribution of the cells. Getting into the neck of the 
flask was avoided as this could cause contamination in the culture. 
10.  Cell culture was incubated for 14 day at 37°C in humidified atmosphere 
containing 5% CO2 was performed. Non-adherent cells were removed on 3 day 
and the medium was changed every 3 days. Approximately 2 weeks later, 
cultured cells were placed into a new flask for expansion. 
 Table 2.1: Complete Mesencult Medium 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Components Amount(ml) 
Mesencult Basal 
Medium 
35 
DMEM 9,5 
FBS 5 
L-Glutamine 0,5 
Total 50 
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2.2.2 Subculture of MSCs 
1. When cells reached 70-80% confluence, medium was discarded and washed with 
PBS one time. 
2. Carefully cells were removed from tissue culture flask with cell scrap and cells 
were transfered and into a 15 ml conical tube. 
3. The tube was centrifugated  at 1500 rpm for 5 minute. Supernatant was discard 
and cells were resuspended in 1-2 ml complete medium. 
4. Cell enumeration was performed and 9 ml of complete medium was placed into a 
T-25 tissue culture flask and 1 ml of stock cell solution (2 x 10
6
 cells per flask) 
was added 
5. until cells become confluent, cultures was Incubated. 
2.2.3 Morphology Analysis 
Morphologic analysis was monitored by Olympus lx71 . 
 
2.2.4 Flow Cytometry 
 
1. After the first passage, the cells were removed by scraps and washed twice with 
PBS. Centrifuged at 1000 rpm for 10 minute.  
2.  1x 106 cells were resuspended in 200 ul PBS and incubated with CD44, CD90 
and CD105, CD45 and CD34 antibodies for 20 min. at room temperature. 
3. The stained cells were analyzed by flow cytometry 
 
2.2.5 Optimization of n-HA/P(VP-co-MAN) Scaffold 
Designed n-HA/P(VP-co-MAN) scaffold optimization was done for the in vitro 
experiments.  Three different approaches were tried.  
1. n-HA/P(VP-co-MAN) slush composite was prepared and mixed in 5:1 and 
1:1 ratio with NaCl. 
2. Mixture was loaded into 1x1 cm mould and dried at 80º C for overnight.  
3. n-HA/NaCl which were prepared in 1:1, 1:2 and 2:1 ratio were put into 
stainless steel mould and 450-psi pressure was applied for 5 minute. 
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4. Scaffolds were fired at 800º C for 2 hours and then fired at 1000ºC for 
overnight. 
5. The other day scaffolds were put into 5 ml polymer solution (50 mg/ml) at 
room temperature for overnight and the next day they were dried at 80 ºC for 
2 hours. 
6. P(VP-co-MAN) slush composite was prepared and dried at 70º C for 2 days 
at vacuum incubator and mixed 1:1 ratio with n-HA/NaCl which were 
prepared in 1:1, 1:2 and 2:1 ratio  
7. Mixture was loaded into stainless steel mould and 450-psi pressure was 
applied for 5 minute. 
8. Scaffolds were put into incubator at 120ºC for 2 days.  
These all dried scaffolds were put into Mesencult medium at 37º C for 48 
hours to remove NaCl and form pores. 
 
2.2.6 In Vitro Differentiation of MSCs to Osteoblast on n-HA/P(VP-co-MAN) 
To determine the influence of n-HA/P(VP-co-MAN) scaffold on the osteogenic    
differentiation of UCB-MSCs, four experimental groups were set up. The groups 
were shown in the Table 2.2. Cell differentiation on scaffold procedure was 
described below. 
1. n-HA/P(VP-co-MAN) scaffolds were sterilized in incubator at 80°C for 
overnight and presented in the complete osteogenic medium (Table 2.3) for 24 h. 
2. MSCs which were cultured in complete medium (Table 2.1) for 1 week were 
seeded onto tops of the prewetted scaffold (2 x 10
6 
cells/ scaffold)in the wells of 
tissue culture plates. 
3. The scaffolds were left undisturbed in an incubator for 3 hr to allow the cells to 
attach to them. 
4. Additional 1 ml of complete osteogenic medium was added into each well. 
5. The cell/scaffold constructs were cultured in a humidified incubator at 37°C with 
95% air and 5% CO2 for 7 days.  
6. The medium was changed every 3 days. Osteogenesis takes approximately 21-28 
days and can be seen by the formation of osteoblasts, which are tightly packed 
and linear in shape. 
 
 
31 
 
Table 2.2: Experimental groups 
Groups Content 
A MSCs+ Complete Osteogenic Medium 
B MSCs+ Complete Mesencult Medium 
C MSCs+ n-HA/ P(VP-co-MAN)+ Complete Osteogenic Medium 
D MSCs+ n-HA scaffold+ Complete Osteogenic Medium 
 
Table 2.3: Complete Osteogenic Medium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                             
2.2.7 Alkaline Phosphatase Activity 
Alkaline phosphatase  (ALP) catalyses the hydrolysis of p-nitrophenylphosphate at 
pH 10.4, liberating p-nitrophenol and phosphate, according to the following reaction: 
Components Amounts 
Mesencult Basal Medium 42,5 ml 
Osteogenic Stimulatory 
Supplements 
7,5 ml 
β- Glycerophosphate 175 ul 
Dexamethasone 5 ul 
Ascorbic Acid 250 ul 
Total 50 ml 
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   p-Nitrophenylphosphate + H2O                              p-Nitrophenol + Phosphate (2.1) 
 
 
The rate of p-Nitrophenol formation, measured phoyometrically, is proportional to 
the catalytic concentration of alkaline phophatase present in the sample.  
 
1. The assay conditions were given in below Table 2.4. 
Table 2.4 ALP assay condition 
 
 
 
 
 
2. Adjust the spectrophotometer to zero with distilled water. 
3. Pipette into a cuvette 1.2ml working reagent and 20 ul sample 
4. Mix and incubate for 1 min at 37° C. 
5. Read the initial absorbance (A) of the sample then read absorbance at 1 min. 
intervals thereafter for 3 minutes. 
6. Calculate the difference between absorbances and the average absorbance 
differences per minute (ΔA/min). 
 
CALCULATIONS 
   
Units: one international unit (IU) is the amount of enzyme that transforms 1 µ mol of 
substrate per minute, in standard conditions. The concentration is expressed in unit 
per liter of sample (U/L) 
 
 
Wavelength 405 nm 
Cuvette  1cm light path 
Temperature  37° C 
ALP 
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2.2.8 In Vitro Mineralization Assay 
The measurement of calcium in the sample is based on formation of color complex 
between calcium and o-cresolphtalein in alkaline medium: 
 
 
       Ca
++
 + o-cresolphtalein                                     Colored complex (2.2) 
 
The intensity of the color formed is proportional to calcium concentration in the 
sample. 
1. The assay conditions are given in below Table 2.5. 
Table 2.5 Mineralization assay condition 
 
   
 
 
 
               
2. Adjust the spectrophotometer to zero with distilled water. 
3. Pipette into a cuvette Blank,Standard and sample as shown in Table 2.6. 
 
Table 2.6 Preperation of mineralization samples 
 
 
 
 
 
 
 
 
 
 
Wavelength 570 nm 
Cuvette  1cm light path 
Temperature  37° C 
 Blank Standard Sample 
Ethanolamine 
buffer 
2 ml 2 ml 2 ml 
Chromogen 1 drop 1 drop 1 drop 
Standard -- 20 ul -- 
Sample -- -- 20ul 
OH
+
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4. Mix and incubate for 5 min. at 37 °C 
5. Read the absorbance (A) of the samples and calibrator, against the Blank. The 
color is stable for at least 40 minutes. 
CALCULATIONS 
           Sample/ standard x (dilution factor) x (conservation factor) = mmol/L calcium  
2.2.8 ESEM Micrographs Observation 
No special preparation (conductive coating) is necessary for examined samples using 
an environmental scanning electron microscope (ESEM) This technique allows for 
real time visual observation of interaction between osteoblast cells and n-HA/ P(VP-
co-MAN) scaffold. 
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3. RESULTS 
3.1 Isolation and culture of MSCs from UCB  
The whole cord blood mononuclear cells were isolated by gradient density 
centrifugation with Ficoll-paque. Culture showed heterogeneity during the first 4 
days. Two different type of cells adhesion was observed which are osteoclast like 
cells and mesenchymal like cells. The morphology of osteoclast like cells are 
heterogeneous and oval/round shape with smooth border and mesenchymal like cells 
were recognizable as adherent cells with a fibroblast-like appearance (Figure 3.1A).  
      
  
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Morphology of primary cultured human UCB cells (A) Adherent cells in 
the culture. Osteclast like cells are oval/round shapes, MSCs are 
fibroblast-like cells on day 7(x 20). (B) Confluent cells on day 14 (x10). 
The floating cells were removed from the culture through continuous change of 
medium. the primary culture cells reached confluence 15-20 days later (Figure 3.1 
B). After the confluency cells were subcultured and osteoclats-like cells were 
became fewer.  
 
 
A B 
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3.2 Immunophenotypes of MSCs  
A selection of surface markers was tested by flow cytometric analysis. MSCs are 
negative for CD 34 and CD 45 and positive for CD 44, CD90 and CD 105 markers 
(Figure 3.2). Non-labeled cells were used as a negative control to prevent 
background flouresence.  10.000 cells were stained and counted by flow cytometry.  
12 % percent of 10.000 labeled cells were mononuclear cells and 24 % percent of 
mononuclear cells were CD 44 positive cells. 10.000 labeled cells were counted 
again for CD 90 and CD105 and 22.2 % percent of mononuclear cells were positive 
for these markers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                      
 
 
 
 
 Figure 3.2   Immune phenotype of MSC, samples were shown on t left and negative  
                   controls were on right. 
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3.3 Optimization of n-HA/P(VP-co-MAN) Scaffold 
Biodegradability and porosity are important part of scaffold for tissue engineering. 
Therefore, designed scaffolds were immersed in medium for 48 hours. After that 
time optimum composite concentration and NaCl content was discovered. While 
some of scaffolds dispersed, fired scaffolds preserved their shapes, which were 
shown in Figure 3.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Optimization of scaffolds in Mesencult Medium (A) moulded and   
kkkkkkk     sterilized scaffolds (B) scaffolds in medium for 48 hours (C-D) dispersed  
k                 scaffolds. 
n-HA/NaCl which were prepared in 1:1, 1:2 and 2:1 ratio, preserved their shapes 
but when these scaffolds were put into new dishes, 1:2 and 2:1 n-HA/NaCl 
scaffolds were broken, so 1:1 n-HA/NaCl composite were used for he 
differentiation experiments. 
Latterly, scaffold was checked for its polymer content because polymer can be 
degraded in that time. For that purpose FTIR analysis was done (Figure 3.4). 
Control group which were HA, 1/1 HA/P obtained from Erdem Tezcan’s master 
thesis. 89 h HA/P were waited in the medium for 89 hours and it preserved its 
shapes.  After the analysis we saw that the pattern of 89 h HA/P was as same as 1/1 
HA/P. Because of the humid 89 h HA/P composite, there were small differences 
about their curve. 
A B 
C D 
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Figure 3.4 FTIR analysis of n-HA/P(VP-  co MAN) 
 
3.4 ESEM Micrographs Observation 
The structure of the porous scaffolds consists of pores with around 70% of porosity 
(Figure 3.5), presenting a size between 10 and 50 µm. These values are within the 
range of those  ideal for adhesion of cells however values should be around  200-500 
µm for tissue engineering of bone. Nearly 50 µm NaCl was used to obtain  porous 
structure. Porousity helps the cells to contact each others. 
 
Figure 3.4 Morphological analysis of n-HA/P(VP-  co MAN).Scale bar 50 µm for A   
b               and 20 µm for B 
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As seen in the Figure 3.4, surface of the scaffold was not smooth. The wavy areas 
providing the proper surface area to facilitate the adhesion of cells. Also scaffolds 
ideally should have in porous structure. Our scaffold was presenting a size of 
porosity between 10 and 50 µm. Although this is not assumed as ideal pore size for 
bone tissue engineering. We found that but the cells adhesion was good and cell 
proliferation was obtained through contacting of cells with each other horizontally.  
 
3.5 In Vitro Differentiation of MSCs to Osteoblast on n-HA/P(VP-co-MAN) 
We first examined the cell adhesion. Three days later experimental group A, B, C 
which were in complete mesencult medium were checked for the adhesion of the 
MSCs by Olympus lx71  [Figure 3.6 (A, C, E)]. Unconnected cells were removed 
from the culture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Phase contrast images of HUCB cells. (A) MSCs on n-HA/P(VP-  co  
dddd          MAN) x10, (C) MSCs with n-HA, (E) MSCs , (B) differentiating MSCs     
dddd    on n-HA/P(VP-co-MAN) (D) differentiating MSCs on n-HA (F) 
ddddddddddifferentiating MSCs, x40. 
 
A B 
C D 
E F 
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Following the confirmation of  adhesion and proliferation of the MSCs, the medium 
was removed and next complete osteogenic medium was added onto cells. Following 
the 3 days of incubation time, MSCs were found to begin to differentiate to form 
osteoblast cells [Figure 3.6 (B, D, F)]. As shown in the figure with arrow, 
mesencyhmal stem cells starts to change their shape. Round contours start to form 
with extension around the cells. 
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4. DISCUSSION & CONCLUSION 
Over the past several years, many researchers have identified, isolated and 
characterized the Mesenchymal Stem Cells from different tissue sources. Due to the 
development of cell separation techniques, cultivation of MSCs is more advanced.  
MSCs have the capacity of self- renewal and differentiation into various lineages of 
mesenchymal tissues under appropriate conditions. In recent years, these properties 
of MSCs made them very attractive for tissue engineering applications and cell based 
therapeutic applications. MSCs reside within the connective tissues of most organs 
and in addition, MSCs can migrate to the sites of injury, inflammation, and to tumors 
[84; 85] for repairing. Although MSCs can be isolated from multiple tissue types, 
bone marrow stroma is still the most known tissue source utilized in growing MSCs. 
It is now known that use of autologous transplants for bone defects is lowering the 
risk of immune rejection. Still, the age of donor has a critical importance for that 
kind of applications due to gradually decreasing frequency of presence of MSCs 
within the marrow stroma. Therefore, search for alternative sources of MSCs with 
higher proliferative potency and differentiation capacity has gained priority. 
Recently, several groups isolated MSCs from UCB due to their fetal origin, 
proliferative and differentiation potential [86]. 
To restore skeleton function in fractures and traumas, bone tissue regeneration 
remains an important challenge. In recent years, different scaffold constructs has 
been constructed toward developing tissue-engineered alternatives to autologous 
bone grafting [36]. Developing 3D biomimetic scaffold provides simulated natural 
environment for stem cell differentiation. It is highly desirable to replicate as closely 
as possible the natural ECM, both in terms of chemical composition as well as 
hierarchical architecture from the nano-scale to the macrostructure [67]. 
In this study, we used MSCs derived from human umbilical cord blood in 
conjunction with Hydroxapatite/Poly(N-vinyl-2-pyrrolidone-co-malec acid) [n-
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HA/P(VP-co-MAN)]. There are various methods to isolate MSCs from UCB, 
including flow cytomery, gradient density centrifugation and/or immunomagnetic  
selection. We used Ficoll-Paque (1.077g/mL) combined the gradient density 
centrifugation to isolate MSCs from UCB however culture showed heterogeneity 
during the first 4 days. Therefore, culture medium was changed with 3 days intervals 
to remove flattened cells. Morphologic profile of MSCs as shown at Figure 3.1 was 
similar to earlier works. Although, the method combining gradient density 
centrifugation and Ficole-Paque is one of the easiest and cheapest ways to isolate 
MSCs, the culture may still contain hematopoietic cells which can be lysed by 
ammonium chloride buffer. On the other hand, for clinical applications, using the 
other mentioned methods such as flow cytometry and immunomagnetic selection 
will be the best choices in order to gain a pure MSC culture. 
For this study, the isolated and cultured MSCs were analyzed by the flow cytometry 
and gated for granularity, size and surface markers. The gated cells were analyzed for 
the expression of cell membrane protein markers and found negative for CD45-CD34 
hematopoietic markers and positive for CD44, CD90 and CD 105, which are 
generally considered for markers of MSCs. CD44 surface marker is an adhesion 
molecule whereas CD90 and CD105 are membrane glycoprotein located on cell 
surfaces and affecting cell morphology and migration.  Expression levels of these 
surface markers might be down-regulated during expansion and aging, due to cell-to-
cell contact and plastic adherence. Fibroblasts are also expressing CD105 and CD73 
and are negative for CD45- CD34 markers and osteoblastic, chondrogenic, 
adipogenic differentiation from fibroblasts has also been described. Many different 
properties of fibroblasts are similar with MSCs, therefore the known surface proteins 
described for the characterization of MSCs are not sufficient to distinguish between 
different cell types [87; 88]. 
In order to prove that the isolated cells are MSCs, differentiation assays using 
induction of reagents such as osteogenic, adipogenic and endothelin stimulant 
medium, can be used. In our study, we seeded UCB- MSCs on a biomimetic artificial 
bone scaffold material named n-HA/P(VP-co-MAN), which exhibits certain features 
of natural bone, with osteogenic stimulant medium. Our result showed that n-
HA/P(VP-co-MAN) scaffold supports the proliferation and differentiation of MSCs 
to osteoblasts.  P(VP-co-MA) polymer is biodegradable, soluble in water and highly 
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hydrophilic. P(VP-co-MA) has many electrophilic groups so it can chealate with 
metals and can be used in tissue engineering area. The hydrophobic surfaces of most 
synthetic polymer biomaterials are unfavorable to osteogenic cells because they 
show a lower proliferative rate and a higher apoptotic rate than hydrophilic surfaces. 
Therefore, the addition of ceramics such as hydroxyapatite to polymers make them 
hydrophilic and as well as osteoconductive [69]. On the other side, P(VP-co-MA) is 
hydrophilic but not osteoconductive. Enhancing osteoconductive of P(VP-co-MA), 
hydroxyapatite was crosslinked to polymer. All these properties make n-HA/P(VP-
co-MAN) scaffold more attractive than already existing scaffolds for bone tissue 
engineering. 
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APPENDICES 
 
APPENDIX A  
 
LABORATORY EQUIPMENT 
 
 
Pipettes     : Pipetteman P10, Eppendorf 
Microscope    : Olympus IX71 
Incubator    : Thermo electron corporation Hera cell 240       
Laminar air flow cabin  : Hera safe KS12 
 
Centrifuge    :Beckman coulter 
 
Flow cytometer   : Beckman coulter 
 
Water distillation system  : Millipore 
 
Microplate Reader   : Biorad 
                                
Deep freezes and refrigerators         : Heto Polar Bear 4410 ultra freezer, JOUAN 
Nordic A/S, catalog# 003431 
: 2021 D deep freezer, Arcelik. 
: 1061 M refrigerator, Arcelik 
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APPENDIX B 
 
 
CHEMICALS 
 
 
 
MARKERS 
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APPENDIX C  
 
MEDIUMS and BUFFERS 
Phosphate buffered saline (PBS) buffer: 
Dilute the 5 ml 10 X PBS buffer with 45 ml distillated water for making 1x PBS 
buffer. 
Complete Mesencult Medium:  
Mix the components shown in the below Table A.1. 
Table A.1 Preparation of complete Mesencult Medium 
 
Complete Osteogenic Medium:  
Mix the components shown in the below Table A.2 
 
Table A.2: Preparation of Complete Osteogenic Medium 
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